Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation

Table 3 Multivariable predictors of major adverse cardiovascular events (MACE) during acalabrutinib use.*

Variable	Hazard ratio	95% CI	p value
New/Worsened HTN versus No/Stable HTN**	1.13	(0.52 – 2.46)	0.759
Age ≥ 65	2.07	(1.02 – 4.18)	0.043
Sex: Female vs. Male	0.51	(0.20 – 1.26)	0.143
Number of prior anticancer therapies	1.05	(0.91 – 1.21)	0.521
Prior DM	0.94	(0.32 – 2.76)	0.905
Prior CKD	1.11	(0.22 – 5.63)	0.903
Prior AF/Aflutter	3.66	(1.68 – 7.94)	0.001
Prior CVA/TIA	2.60	(0.58 – 11.63)	0.212
Prior targeted agent therapies (not ibrutinib)	1.45	(0.54 – 3.88)	0.452

Bold indicates statistical significance, using the significance level α = 0.05
AF atrial fibrillation, Aflutter atrial flutter, BMI body mass index, CI confidence interval, CKD chronic kidney disease, CVA cerebrovascular accident, DM diabetes mellitus, HTN hypertension, TIA transient ischemic attack. *MACE includes the combined outcome of AF, CHF, CVA, MI (myocardial infarction), VF/VT (ventricular fibrillation/ventricular tachycardia), and cardiovascular death during acalabrutinib use. **HTN as non-time-varying

ISSN: 1756-8722